Angeliq Regulatory Post Marketing Surveillance

Completed

• Conditions: Postmenopausal Period; Osteoporosis, Postmenopausal
• Interventions: Drug: E2/DRSP (Angeliq, BAY86-4891)

• Registration Number: NCT01064453
• Lead Sponsor: Bayer

Brief Summary

Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA). This is non-interventional , prospective, multi-center study.Target number of patients is 4500.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-06
• Study First Submitted: 2010-02-05
• Study First Submitted QC: 2010-02-05
• Study First Posted: 2010-02-08
• Primary Completion: 2012-12
• Study Completion: 2012-12
• Status Verified: 2013-11
• Last Update Submitted: 2013-11-18
• Last Update Posted: 2013-11-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 4078

Inclusion Criteria

• Hormone replacement therapy for estrogen deficiency symptoms in postmenopausal women more than 1 year postmenopause
• Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis

Read More

Exclusion Criteria

• Undiagnosed genital bleeding
• Known, past or suspected cancer of the breast
• Known or suspected estrogen-dependent malignant tumors (e.g. endometrial cancer)
• Untreated endometrial hyperplasia
• Previous idiopathic or current venous thromboembolism (e.g. deep venous thrombosis, pulmonary embolism)
• Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction)
• Acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal
• Porphyria
• Severe renal insufficiency or acute renal failure
• Known hypersensitivity to the active substances or to any of the excipients

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group 1	E2/DRSP (Angeliq, BAY86-4891)	-

Primary Outcome Measures

Name	Time	Method
Adverse event collection	At each visit of patient during observational period (6 months)

Secondary Outcome Measures

Name	Time	Method
Improvement of menopausal symptoms	After 6 months or at discontinuation of Angeliq (At earlier point)